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ABSTRACT 
Objective: The study was aimed at evaluating the folkloric use of the Catunaregam spinosa (Thunb) bark for its hypoglycaemic and antioxidant 
activity against dexamethasone-induced diabetes in wistar rats.  
Methods: Diabetes was induced in wistar rats by dexamethasone administration 10 mg/kg, b. wt., s. c for 11 consecutive days to all group animals 
(except Group I). After confirmation of diabetes, the animals were divided into 5 groups (n=6). Group I: Vehicle control treated with normal saline 
only, Group II: Diabetic control treated with dexamethasone only, Group III: Standard control treated with dexamethasone plus glibenclamide (5 
mg/kg, b. wt., p. o), Group IV and V: Test control received dexamethasone plus ethanolic extract of Catunaregam spinosa (EECS) at graded doses of 
200 mg/kg, b. wt. and 400 mg/kg, b. wt., p. o for 21days respectively. On the last day of the experiment, the effect of Catunaregam spinosa bark was 
measured by estimating the biochemical and antioxidant parameters. 
Results: There was a significant alteration in the serum glucose, HbA1c, total proteins, serum lipid profile and tissue antioxidant parameters in 
dexamethasone-treated animals when compared to the normal control rats. 
In test groups treated with glibenclamide and EECS, it was significantly ameliorated the altered parameters such as serum glucose, HbA1c, total 
proteins, serum lipid profile and the antioxidant parameters like SOD, CAT, GSH and MDA when compared to dexamethasone-treated animals with 
evidence of histopathological studies of the pancreas.  
Conclusion: The results indicated that the ethanolic extract of Catunaregam Spinosa (Thunb) bark has shown the hypoglycemic and antioxidant 
property. 
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Diabetes mellitus is a metabolic disorder characterized by an 
abnormality in carbohydrate, lipid and protein metabolism resulting 
in chronic hyperglycemia and abnormality of lipid profile. Chronic 
hyperglycemia of diabetes is associated with long term damage, 
dysfunction and eventually the failure of organs, especially the eyes, 
kidneys, nerves, heart and blood vessels [1]. Environmental factors 
such as diet, obesity, sedentary lifestyle and other factors like high 
family aggregation, insulin resistance, nutritional status, age 
increase the risk of diabetes [2]. Diabetes is managed with drugs 
such as metformin, sulfonylureas, thiazolidinedione’s etc and as well 
as artificial insulin [3, 4]. The serious adverse side effects like liver 
problems, lactic acidosis and diarrhoea [5, 6]. Diabetes is currently 
affecting around 143 million people [7], the number of those affected 
is increasing day by day by 2030 and it is predicted to reach 366 
million populations worldwide [8]. Management of diabetes without 
any side effects is still a challenge for the medical system. This leads 
to an increasing search for improved anti-diabetic drugs [9].  
Medicinal plants have been used in the Indian traditional system of 
medicine and have shown anti-diabetic activity [10, 11]. The number 
of active constituents present in medicinal plants is thought to act on 
a variety of targets by different mechanisms. Catunaregam spinosa 
(Thunb) belongs to the family Rubiaceae is commonly known as 
Gedhpal or Emetic nut. This species is common as undergrowth in 
the sub-Himalayan tract [12]. The raw fruits have a highly astringent 
taste due to high tannin content. The seeds contain essential oil and 
organic acid. The dried and powdered fruit pulp is credited with 
emetic properties [13]. Plant bark is reported for diarrhoea, 
dysentery, abortifacient, antihelminthic and antipyretic [14]. It is 
also considered to be a sedative, hypoglycaemic and stomach ache as 
first aid remedy. Roots are used in the treatment of epilepsy, eye 
ache and urinary infection. The fruit is used as emetic and the leaves 
are used in pulmonary infections [15, 16]. Catunaregam spinosa also 
used as carminative, antipyretic, cures abscess, ulcers, 
inflammations, wounds, tumours and skin diseases [17]. Based on 
the scientific evidence of the data, the research was carried out to 
evaluate the hypoglycaemic and antioxidant activity of ethanolic 
extract of Catunaregam spinosa (Thunb) (EECS) bark against 
dexamethasone-induced diabetes in wistar rats.  
MATERIALS AND METHODS 
Collection and authentication of plant specimen 
The stem barks of Catunaregam spinosa (Thunb) were collected 
from surrounding areas of Seshachalam hills, Chittoor district and 
Andhra Pradesh (A. P). The plant material was authenticated by Dr. 
K. Madhava chetty, Professor, Department of Botany, Sri 
Venkateswara University, Tirupati, A. P, and India. 
Animals 
Healthy Adult Male Wistar rats weighing 150-200 gms were 
procured from Raghavendra enterprises, Bangalore and were 
maintained under standardized environmental conditions 12-h 
light/dark cycle, 24 °C and 35 to 60% humidity, provided free access 
to pellet diet and purified drinking water ad libtium. The 
experimental protocol was approved by Institutional Animal Ethical 
Committee of Krishna Teja Pharmacy College, Tirupati, A. P 
(Registered No. 1521/P0/11/CPCSEA-Committee for the purpose of 
control and supervision of experimental animals).  
Preparation of plant extract 
The plant barks were isolated, washed, shade dried and 
mechanically grinded to coarse powder. The powdered drug was 
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subjected to continuous hot percolation with solvent 70% ethanol 
using soxhlet apparatus with 1:4 volumes. The extraction was 
carried out until the solvent becomes colourless and the solvent was 
removed from the extract by evaporation. The dried extract thus 
obtained was preserved in desicator [18]. The EECS was evaluated 
for phytochemical constituents using standard procedures [19, 20]. 
Experimental design 
Experimental rats were taken and divided into five groups each 
containing six animals. 
Group I animals served as vehicle control received 0.5 ml of normal 
saline orally. 
Group II animals served as diabetic control received dexamethasone 
(10 mg/kg, b. wt., s. c) for 11 consecutive days [21]. 
Group III animals served as standard control received 
dexamethasone (10 mg/kg, b. wt., s. c) for 11days and glibenclamide 
(5 mg/kg, b. wt., p. o) for 21 d.  
Group IV and V animals served as test control received dexamethasone 
(10 mg/kg, b. wt., s. c) for 11 d and EECS at graded doses of 200 mg/kg, b. 
wt., and 400 mg/kg, b. wt., p. o for 21days respectively. 
Assessment of the hypoglycemic effect 
The blood samples were collected through retro-orbital route from 
each rat under mild ether anesthesia on 22nd day and serum was 
separated by centrifugation of blood at 4000 rpm for 10 min. The 
serum was used for the estimation biochemical parameters such as 
Glycosylated haemoglobin (HbA1
Statistical analysis 
c), serum glucose levels, Total 
cholesterol (TC), Triglycerides (TGL), High density lipoprotein 
(HDL), Low density lipoprotein (LDL), Very low density lipoprotein 
(VLDL) [22-26] and total protein (TP) [27]. From each group, one 
animal were taken and sacrificed for pancreas isolation and same 
one part is used for estimation of antioxidant parameters like 
Superoxide dismutase (SOD), Catalase (CAT), Glutathione reductase 
(GSH) and Malondialdehyde (MDA) [28-31] and another part 
processed for Histopathological studies [32]. 
The results were expressed as mean±SEM/SD differences in groups 
for biochemical estimations. Statistical analysis was determined by 
one way–analysis of variance (ANOVA), individual groups were 
compared using Dunnett’
RESULTS 
s t-test. P value<0.05 has been considered 
as a statistical significance level. 
Preliminary phytochemical screening of EECS revealed the presence 
of Carbohydrates, Glycosides, Saponins, Terpenoids, Phenols, 
Tannins, Flavonoids, Proteins, Amino acids and Phytosterols.  
Acute toxicity studies and test dose selection 
The acute toxicity studies were conducted as per OECD 
(Organization for economic co-operation and development) 423 
guidelines (Acute Toxic Class Method). No sign of toxicity and 
mortality was observed up to the maximum dose administered a 
dose of 2000 mg/kg, b. wt. p. o of EECS. The dose was selected based 
on the maximum dose administered with 1/10th and 1/20th
Effect of EECS on HbA
 as low 
dose and a high dose of test extract. 
1
Table 1 represents a significant (P<0.001) increased in the level of 
glycosylated haemoglobin (HbA1c) and decreased in the serum total 
protein levels upon administration of dexamethasone as compared 
to the vehicle-treated animals. Upon treatment with standard drug 
glibenclamide (5 mg/kg, b. wt., p. o) and EECS at both dose levels 
(200 mg/kg, b. wt., and 400 mg/kg, b. wt., p. o) for 21 d showed a 
significant (P<0.05) (P<0.01) restoration of the abnormal levels 
compared to the diabetic control rats. 
c and serum total protein  
 
Table 1: Effect of EECS on HbA1
Groups 
c and serum total protein in dexamethasone-induced diabetic rats 
Glycosylated Haemoglobin-HbA1 Total protein (mg/dl) c (%) 
Vehicle control 5.22±0.661 6.780±0.947 
Diabetic control  8.58±0.568 4.600±0.687 
Standard control 5.14±0.683 6.260±0.598*** 
EECS-I (200 mg/kg, b. wt.) 
*** 
5.88±0.624 4.924±0.778** 
EECS-II (400 mg/kg, b. wt.) 
* 
5.70±0.870 5.960±0.969*** *** 
Values were expressed as mean±SEM (n=6). *P<0.05, **P<0.01,***P<0.001. As compared with diabetic control (One-way ANOVA followed by 
Dunnett’s test). 
 
Effect of EECS on serum glucose levels 
Table 2 shows dexamethasone administration raised the serum 
glucose levels significantly (P<0.001) on day 4, 7, 10, 15 and 21 
leading to hyperglycemia when compared to the vehicle control 
animals. Reversal of raise in serum glucose level was found in the 
animals treated with standard drug glibenclamide (5 mg/kg, b. wt., 
p. o) and EECS at both dose levels (200 mg/kg, b. wt., and 400 
mg/kg, b. wt., p. o) for 21 d when compared to the diabetic control 
rats.
 
Table 2: Effect of EECS on serum glucose levels in dexamethasone-induced diabetic rats 
Groups Serum Glucose Levels (mg/dl) 
4th 7 day th 10 day th 15day th 21 day st day 
Vehicle control 85.0±3.536 88.0±2.550 89.2±1.772 91.0±2.646 97.33±1.333 
Diabetic control  159.2±2.933 197.4±2.098 210.0±2.450 217.0±1.453 219.67±2.881 
Standard control 103.4±1.715 99.80±1.020*** 94.80±1.655*** 92.67±1.333*** 88.67±2.881*** 
EECS-I (200 mg/kg, b. wt.) 
*** 
127.6±1.806 121.0±1.049** 110.4±1.678** 108.3±1.332** 105.67±1.373** 
EECS-II (400 mg/kg, b. wt.) 
** 
110.4±1.852 105.4±2.821*** 103.8±3.513*** 97.00±1.577*** 94.00±1.577*** *** 
Values were expressed as mean±SEM (n=6). *P<0.05, **P<0.01, ***P<0.001. As compared with diabetic control (One-way ANOVA followed by Dunnett’s test) 
 
Effect of EECS on serum lipid profile 
Table 3 demonstrates that dexamethasone for 11 consecutive days 
causes an imbalance in lipid metabolism provokes hyperlipidemic 
condition in rats with significant (P<0.001) elevation of TC, TGL, LDL, 
VLDL and decrease in the HDL levels when compared to the vehicle 
control rats. Treatment with standard drug glibenclamide (5 mg/kg, b. 
wt., p. o) and EECS at both dose levels (200 mg/kg, b. wt., and 400 mg/kg, 
b. wt., p. o) for 21 d showed a significant (P<0.05) (P<0.01) amelioration 
of abnormal lipid profile when compared to the diabetic control rats. 
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Table 3: Effect of EECS on serum lipid profile in dexamethasone-induced diabetic rats 
Groups Serum lipid profile (mg/dl) 
Total cholesterol Triglycerides HDL LDL VLDL 
Vehicle control 181.8±5.936 146.2±2.663 44.0±1.703 41.00±1.316 11.60±1.509 
Diabetic control  265.8±10.220 177.2±2.728 23.6±1.80 93.20±3.374 33.60±1.034 
Standard control 190.8±3.338 148.6±2.064*** 42.2±2.969*** 52.80±2.374*** 12.60±0.924*** 
EECS-I (200 mg/kg, b. wt.) 
*** 
213.0±4.447 161.0±3.894* 37.2±2.489* 67.00±2.447* 19.20±0.884** 
EECS-II (400 mg/kg, b. wt.) 
** 
195.4±3.749 154.0±2.140*** 40.0±2.316*** 57.20±2.374** 14.80±0.374*** *** 
Values were expressed as mean±SEM (n=6). *P<0.05, **P<0.01, ***P<0.001. As compared with diabetic control (One-way ANOVA followed by Dunnett’s test) 
 
Effect of EECS on tissue pro-oxidant and anti-oxidants 
Table 4 demonstrates that dexamethasone induction caused 
significant (P<0.001) decrease in the antioxidant enzymes like 
SOD, CAT, GSH and increase in the LPO levels indicating that 
production of reactive oxygen species leading to free radical 
damage when compared to the vehicle control rats. Treatment 
with standard drug glibenclamide (5 mg/kg, b. wt., p. o) and EECS 
at both dose levels (200 mg/kg, b. wt., and 400 mg/kg, b. wt., p. o) 
for 21 d showed a significant (P<0.05) (P<0.01) reversal of 
abnormal pro-oxidant and antioxidant enzymes when compared to 
the diabetic control rats. 
 






 consumed/mg protein) (µg of GSH/mg protein) 
LPO 
(nM of MDA/mg protein) 
Vehicle control 18.20±1.583 32.00±0.816 29.40±0.509 45.80±2.374 
Diabetic control 8.680±1.080 22.80±0.874 12.40±0.509 91.60±2.509 
Standard control 16.00±1.316 31.00±0.812*** 27.80±0.633*** 49.40±1.28*** 
EECS-I (200 mg/kg, b. wt.) 
*** 
13.40±1.509 28.80±0.972* 24.60±0.599* 65.00±2.362** 
EECS-II (400 mg/kg, b. wt.) 
** 
15.00±1.312 30.40±0.949** 26.60±0.897** 54.00±1.312*** *** 
Values were expressed as mean±SEM (n=6). *P<0.05, **P<0.01, ***P<0.001 as compared with diabetic control (One-way ANOVA followed by Dunnett’s test) 
 
 
Fig. 1: Normal control (Group I)-Received normal saline has shown 
the normal architecture of pancreatic tissue with islet of 
langerhans and acinar cells. (Abbreviation: EX-Exocrine, AC-Acinar) 
 
 
Fig. 2: Diabetic control (Group II)-Treated with dexamethasone 
10 mg/kg s. c. observed congestion, degenerative changes and 
necrotic changes in pancreatic cells indicate structural damage 
of pancreas. (Abbreviation: C-Congestion, DC-Degenerative 
changes, NC-Necrotic changes) 
 
Fig. 3: Standard group III-treated with dexamethasone (10 
mg/kg, s. c) and glibenclamide (5 mg/kg, p. o.)-the regeneration 
of pancreatic tissue shows similar to normal cytoarchitecture. 
(Abbreviation: EX-Exocrine, AC-Acinar) 
 
 
Fig. 4: Test 1 (EECS 200 mg/kg)-The regeneration of pancreatic 
tissue takes place and shows similar to normal 
cytoarchitecture. (Abbreviation: AC-Acinar, IL-Islets of 
langerhans) 
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Fig. 5: Test 2 (EECS 400 mg/kg)-regenerative changes take place 
in pancreatic tissue and show similar to normal 
cytoarchitecture. (Abbreviation: EX-Exocrine, AC-Acinar) 
 
Histopathological studies 
Dexamethasone administration for 21 d revealed that the pancreas 
with degeneration of pancreatic cells and inflammation vacuoles 
may be due to the free radical damage compared to the normal 
vehicle control with normal parenchymatous cell without any 
degeneration and inflammation. Treatment with glibenclamide and 
EECS significantly reduced the marked inflammation and 
degeneration of pancreas as compared to the diabetic control rats. 
DISCUSSION 
In the present study Catunaregam spinosa (Thunb) was selected for 
hypoglycaemic and antioxidant activity evaluation owing to its 
ethnomedicinal use in curing diabetes. Therefore, the study was 
undertaken to justify its claimed use. Ethanolic extract of 
Catunaregam spinosa (Thunb) (EECS) bark was prepared by soxhlet 
method and stored in the refrigerator at 4 °C. Rats were selected as 
experimental animals for evaluating anti-hyperglycemic and 
antioxidant activity. Acute toxicity was conducted as per OECD 
guidelines and the EECS was not showed any toxicity at the dose of 
2000 mg/kg and no death was reported for 72h. Preliminary 
phytochemical screening of EECS revealed the presence of 
Carbohydrates, Glycosides, Saponins, Terpenoids, Phenols, Tannins, 
Flavonoids, Proteins, Amino acids and Phytosterols.  
Subcutaneously administration of dexamethasone for 11 d causes 
significant (P<0.001) elevation of HbA1c and decrease in the serum 
total protein levels in diabetic control rats as compared to the 
vehicle control. Glucocorticoids are widely used therapeutic tools 
particularly in treatment for anti-inflammatory and immune-
modulatory purposes. Side effects of glucocorticoid treatment 
include steroid diabetes [33, 34]. It induces hyperglycemia is 
partially due to increased hepatic glucose production and insulin 
resistance of peripheral tissues. Moreover, glucocorticoids are 
known to inhibit insulin secretion [35, 36]. The underlying 
mechanism involves increased α2-adrenoceptor signaling [37], 
increased Kv channel activity [38] and impaired glucose metabolism 
[39, 40]. They diminish glucose utilization in the peripheral tissues 
cause an increase in protein breakdown by increasing the synthesis 
of glutamine and lipolysis, thereby providing amino acids and 
glycerol for gluconeogenesis [41]. HbA1c as a biomarker for 
monitoring the levels of glucose among type 2 diabetic patients 
provides a reliable measure of chronic glycaemia and correlates well 
with the risk of long-term diabetes complications. So that it is 
currently considered the test of choice for monitoring and chronic 
management of diabetes [42]. During diabetes, the excess of glucose 
present in the blood reacts with hemoglobin to form glycosylated 
haemoglobin [43]. The rate of glycation is proportional to the 
concentration of blood glucose [44, 45]. Treatment with 
glibenclamide and EECS 200 mg/kg and 400 mg/kg b. wt, p.o. 
ameliorated the abnormal levels of HbA1c and TP when compared to 
the diabetic control rats depicted in table 1.  
In the present study, it has been found that the elevation of serum 
glucose and abnormal changes in the lipid profile in dexamethasone-
treated rats indicating that the hyperglycemia and Hyperlipidemia 
[46, 47]. Dexamethasone increases in glucose levels leading to 
hyperglycemia due to the inhibition of GLUT-4 (glucose transporter) 
translocation from intracellular compartments to the plasma 
membrane particularly of skeletal muscles [48, 49]. The elevation of 
serum glucose levels in diabetic control rats were significantly 
restored upon treatment with the standard glibenclamide and 
ethanolic extract of Catunaregam spinosa (Thunb) at both dose 
levels (200 mg/kg, b. wt., and 400 mg/kg, b. wt., p. o.) for 21 d as 
compared to the vehicle control rats which was depicted in table 2. 
The possible mechanism by which EECS mediated its anti-
hyperglycemic effect could be by the potentiation of pancreatic 
secretion of insulin from existing β-cells of islets thereby increase 
glucose utilization from tissues through GLUT-4.  
Pharmacological doses of glucocorticoids induce ob gene expression 
in rat adipocyte tissues within 24 h which is followed by complex 
metabolic changes like hyperleptinemia, resulting in decreased in 
food consumption, with enhanced blood glucose and an imbalance in 
lipid metabolism leading to Hyperlipidemia [50-51]. On 
administration of dexamethasone, significantly (P<0.001) elevate 
the serum lipid parameters such as TC, TGL, LDL, VLDL and decrease 
in the HDL levels when compared to the vehicle control rats. 
Treatment with EECS (200 mg/kg, b. wt., and 400 mg/kg, b. wt., p. o.) 
for 21 d had ameliorated the abnormal lipid profile depicted in table 
3. From the results of the present study, it may be suggesting that 
improvement in food intake and HDL levels and also a reduction in 
blood glucose. And it confirms that EECS shows protection of vital 
organs like pancreas, liver, heart, spleen and kidney thereby 
reducing the causation of diabetes [52].  
The antioxidant enzymes such as catalase (CAT), glutathione S-
transferase (GST), glutathione peroxidase (GPx) are able to resist 
oxidative stress by scavenging free radicals, inhibiting lipid 
peroxidation, increasing glutathione and catalase activity [53]. 
Oxidative stress can be generated by hyperglycemia and for a long 
time, it has been accused to cause insulin resistance. Insulin 
resistance induces the release of cytokines like TNF-alpha, IL-8 
which leads to the development of oxidative stress in the liver by 
reducing the mitochondrial levels of Cu/Zn SOD, glutathione, 
producing H2O2 radicals and leads to increase in lipid peroxidation 
[54]. On Administration of dexamethasone induces the reduction of 
antioxidant enzymes such as SOD, CAT, GSH and increase in the lipid 
peroxidation when compared to the vehicle control animals. EECS 
(200 mg/kg and 400 mg/kg) was given orally for 21 d in both doses 
increases the reduced levels of SOD, CAT and GSH thus protecting 
the tissues from oxidative stress by inhibit free radical generation 
and reduce insulin resistance.  
Lipid peroxidation is usually measured through its catabolite 
malondialdehyde (MDA) as a marker of oxidative stress [55, 56]. A 
marked increase in the concentration of MDA in dexamethasone-
induced diabetic rats indicated that enhances lipid peroxidation 
leading to tissue injury and failure of the antioxidant defense 
mechanism to prevent the formation of excess free radicals. EECS 
showed the ability to prevent increased MDA levels in group 4 and 
5 animals, suggesting that EECS inhibited lipid peroxidation and 
improved the pathological condition of diabetes. Hence, the 
possible antioxidant potential of the EECS may be due to the 
presence of polyphenolic compounds i.e. flavonoids and 
phytosterols. 
EECS significantly reduced the marked inflammation and 
degeneration of pancreas as compared to the diabetic control rats. 
While dexamethasone administration revealed that the pancreas 
with degeneration of pancreatic cells and inflammation vacuoles 
may be due to the free radical damage compared to the normal 
vehicle control with normal parenchymatous cell without any 
degeneration and inflammation.  
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Medicinal plants have continued to be a powerful source for new 
drugs contributing about 90% of the newly discovered 
pharmaceuticals. As for the developed countries, the use of herbal 
medicine for chronic diseases is encouraged because there is 
concern about the adverse effects of chemical drugs and treatment 
using medicines of natural origin appears to offer more gentle 
means of managing such diseases. Herbal drugs are prescribed 
widely because of their effectiveness, fewer side effects and are 
relatively low in cost. The above data suggest that the ethanolic 
extract of Catunaregam spinosa (Thunb) bark possess 
hypoglycaemic and antioxidant activity in dexamethasone-treated 
rats as evidenced by the restoration of the abnormal parameter 
levels. This may be due to the presence of bioactive constituents in 
the plant such as tannins, flavonoids, saponins, polyphenols etc. 
Further studies are required to isolate the active principle 
responsible for hypoglycaemic and antioxidant activity. 
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